Teneligliptin/Pioglitazone

特力利汀/吡格列酮

Report date: 2022/07/05 17:29:58
NME

Base Information

Drug NameTeneligliptin/Pioglitazone
Drug Alias NameTeneligliptin + PioglitazoneTeneligliptin (20 mg) + Pioglitazone (15 mg)Zita Plus Pio
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsPeroxisome proliferator-activated receptor γ agonists
TargetsDipeptidyl peptidase IVPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2022/04/25
Country/TerritoryIndia
CombinationsYes Teneligliptin Hydrobromide HydratePioglitazone Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlenmark Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A